Ubidecarenone nanoemulsified composite systems

Carli, F.; Chiellini, Emo; Bellich, Barbara; Macchiavelli, S.; Cadelli, G

doi:10.1016/j.ijpharm.2004.07.048

Cited by 16 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A novel technology by Remedia termed the nanoemulsified composite system (NECÔ) based on the incorporation of a double o/w/o microemulsion into a powder solid microporous carrier was patented and used for developing (CardiumÔ) as a highly bioavailable formulation of CoQ10 (Carli et al, 2005). The microemulsion loaded on the carrier yielded a powder with good flowability, dispersibility but more importantly, improved biopharmaceutical properties revealed by 10 times superior solubilization kinetics in aqueous buffers and three times higher bioavailability than commercial capsules.…”

Section: Emulsifiable Systemsmentioning

confidence: 99%

Strategies for oral delivery and mitochondrial targeting of CoQ10

Zaki

2014

Drug Delivery

View full text Add to dashboard Cite

Coenzyme Q10 (CoQ10), also known as ubiquinone or ubidecarenone, is a powerful, endogenously produced, intracellularly existing lipophilic antioxidant. It combats reactive oxygen species (ROS) known to be responsible for a variety of human pathological conditions. Its target site is the inner mitochondrial membrane (IMM) of each cell. In case of deficiency and/or aging, CoQ10 oral supplementation is warranted. However, CoQ10 has low oral bioavailability due to its lipophilic nature, large molecular weight, regional differences in its gastrointestinal permeability and involvement of multitransporters. Intracellular delivery and mitochondrial target ability issues pose additional hurdles. To maximize CoQ10 delivery to its biopharmaceutical target, numerous approaches have been undertaken. The review summaries the current research on CoQ10 bioavailability and highlights the headways to obtain a satisfactory intracellular and targeted mitochondrial delivery. Unresolved questions and research gaps were identified to bring this promising natural product to the forefront of therapeutic agents for treatment of different pathologies.

show abstract

Section: Emulsifiable Systemsmentioning

confidence: 99%

Strategies for oral delivery and mitochondrial targeting of CoQ10

Zaki

2014

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…An another study demonstrated about 1.2 times improvement in area under curve from CoQ 10 -cyclodextrin complex over crystalline CoQ 10 in rats (Hatanaka et al, 2008). Lipid formulations of CoQ 10 have been extensively studied by many investigators (Kommuru et al, 2001;Nazzal et al, 2002b;Carli et al, 2005), however, there is relatively very less work done in the field of solid dispersion (SD) of CoQ 10 . SD has been demonstrated as a promising technique for improving the bioavailability of poorly water soluble drugs via the enhancement of their solubility and dissolution rate (Chiou and Riegelman, 1971;Leuner and Dressman, 2000).…”

Section: Introductionmentioning

confidence: 99%

Enhancement of solubility and dissolution of Coenzyme Q10 using solid dispersion formulation

Nepal

Han

Choi

2010

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…Various formulations for improvement of the oral bioavailability of CoQ 10 have been investigated, including molecular complexes (Gao et al, 2006;Terao et al, 2006;Ueno, Ijitsu, Horiuchi, Hirayama, & Uekama, 1989), emulsions (Carli, Chiellini, Bellich, Macchiavelli, & Cadelli, 2005;Kang et al, 2004;Kommuru, Gurley, Khan, & Reddy, 2001;Nazzal, Smalyukh, Lavrentovich, & Khan, 2002;Palamakula & Khan, 2004), and liposomal systems (Xia, Xu, & Zhang, 2006;Xia, Xu, Zhang, & Zhong, 2007). Some of the formulations have been confirmed to have greater oral bioavailability of CoQ 10 than standard commercial products do.…”

Section: Introductionmentioning

confidence: 99%